ANXA3 and breast cancer: Doxorubicin and docetaxel. The knockdown of ANXA3 has been demonstrated to promote the uptake of doxorubicin in human MDA-MB-231 breast cancer cells and 4T1 mouse mammary cancer cells (Du et al., 2018).